Wan Y - Search Results

1

Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy.

Simovic B, Walsh SR, Wan Y. Simovic B, et al. Among authors: wan y. Oncolytic Virother. 2015 Oct 15;4:157-67. doi: 10.2147/OV.S66079. eCollection 2015. Oncolytic Virother. 2015. PMID: 27512679 Free PMC article. Review.

2

Potentiating cancer immunotherapy using an oncolytic virus.

Bridle BW, Stephenson KB, Boudreau JE, Koshy S, Kazdhan N, Pullenayegum E, Brunellière J, Bramson JL, Lichty BD, Wan Y. Bridle BW, et al. Among authors: wan y. Mol Ther. 2010 Aug;18(8):1430-9. doi: 10.1038/mt.2010.98. Epub 2010 Jun 15. Mol Ther. 2010. PMID: 20551919 Free PMC article.

3

Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies.

Bastin D, Walsh SR, Al Saigh M, Wan Y. Bastin D, et al. Among authors: wan y. Biomedicines. 2016 Aug 24;4(3):21. doi: 10.3390/biomedicines4030021. Biomedicines. 2016. PMID: 28536388 Free PMC article. Review.

4

HDACi Delivery Reprograms Tumor-Infiltrating Myeloid Cells to Eliminate Antigen-Loss Variants.

Nguyen A, Ho L, Workenhe ST, Chen L, Samson J, Walsh SR, Pol J, Bramson JL, Wan Y. Nguyen A, et al. Among authors: wan y. Cell Rep. 2018 Jul 17;24(3):642-654. doi: 10.1016/j.celrep.2018.06.040. Cell Rep. 2018. PMID: 30021162 Free article.

5

Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.

Walsh SR, Bastin D, Chen L, Nguyen A, Storbeck CJ, Lefebvre C, Stojdl D, Bramson JL, Bell JC, Wan Y. Walsh SR, et al. Among authors: wan y. J Clin Invest. 2019 Feb 1;129(2):518-530. doi: 10.1172/JCI121004. Epub 2018 Dec 18. J Clin Invest. 2019. PMID: 30422820 Free PMC article.

6

Development and applications of oncolytic Maraba virus vaccines.

Pol JG, Atherton MJ, Bridle BW, Stephenson KB, Le Boeuf F, Hummel JL, Martin CG, Pomoransky J, Breitbach CJ, Diallo JS, Stojdl DF, Bell JC, Wan Y, Lichty BD. Pol JG, et al. Among authors: wan y. Oncolytic Virother. 2018 Nov 26;7:117-128. doi: 10.2147/OV.S154494. eCollection 2018. Oncolytic Virother. 2018. PMID: 30538968 Free PMC article. Review.

7

Endogenous T cells prevent tumor immune escape following adoptive T cell therapy.

Walsh SR, Simovic B, Chen L, Bastin D, Nguyen A, Stephenson K, Mandur TS, Bramson JL, Lichty BD, Wan Y. Walsh SR, et al. Among authors: wan y. J Clin Invest. 2019 Dec 2;129(12):5400-5410. doi: 10.1172/JCI126199. J Clin Invest. 2019. PMID: 31682239 Free PMC article.

8

A rational relationship: Oncolytic virus vaccines as functional partners for adoptive T cell therapy.

Burchett R, Walsh S, Wan Y, Bramson JL. Burchett R, et al. Among authors: wan y. Cytokine Growth Factor Rev. 2020 Dec;56:149-159. doi: 10.1016/j.cytogfr.2020.07.003. Epub 2020 Jul 3. Cytokine Growth Factor Rev. 2020. PMID: 32665126 Review.

9

IFNAR blockade synergizes with oncolytic VSV to prevent virus-mediated PD-L1 expression and promote antitumor T cell activity.

El-Sayes N, Walsh S, Vito A, Reihani A, Ask K, Wan Y, Mossman K. El-Sayes N, et al. Among authors: wan y. Mol Ther Oncolytics. 2022 Mar 16;25:16-30. doi: 10.1016/j.omto.2022.03.006. eCollection 2022 Jun 16. Mol Ther Oncolytics. 2022. PMID: 35399605 Free PMC article.

10

HDACi promotes inflammatory remodeling of the tumor microenvironment to enhance epitope spreading and antitumor immunity.

Nguyen A, Ho L, Hogg R, Chen L, Walsh SR, Wan Y. Nguyen A, et al. Among authors: wan y. J Clin Invest. 2022 Oct 3;132(19):e159283. doi: 10.1172/JCI159283. J Clin Invest. 2022. PMID: 35972798 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,406 results

Search Page